Equities analysts expect ContraFect Corp (NASDAQ:CFRX) to post earnings of ($0.10) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ContraFect’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.10). ContraFect posted earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that ContraFect will report full year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.32). For the next year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover ContraFect.
ContraFect (CFRX) opened at $1.50 on Tuesday. ContraFect has a 52 week low of $0.80 and a 52 week high of $2.50.
TRADEMARK VIOLATION WARNING: “-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/13/0-10-earnings-per-share-expected-for-contrafect-corp-cfrx-this-quarter.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.